Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The goal of this randomized controlled trial is to test the efficacy of StrataMGT in the
management of Genitourinary Syndrome of Menopause (GSM) compared to estrogen therapy. The
main question it aims to answer is:
- Will StrataMGT be non-inferior regarding patient quality of life compared to standard of
care?
Participants will use either StrataMGT or estrogen vaginal cream to treat GSM for 3
consecutive months. After the baseline assessment, participants will be assessed monthly for
quality of life, clinical signs, symptoms, pathology and adverse reactions.